Advertisement

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis

Mohamad A. Meybodi, Wenhao Cao, Leo Luznik, Asad Bashey, Xu Zhang, Rizwan Romee, Wael Saber, Mehdi Hamadani, Daniel J. Weisdorf, Haitao Chu and Armin Rashidi

Data supplements

Article Figures & Data

Figures

  • Figure 1.

    Random-effects meta-analysis. Detailed results for cGVHD (A), NRM (B), DFS (C), and grade II-IV acute GVHD (D). (E) A summary of other outcomes. The study by Robinson et al15 was considered separately for patient groups < 55 years of age (first occurrence in each plot) and ≥55 years of age (second occurrence in each plot) years. CI, confidence interval; HR, hazard ratio.

Tables

  • Table 1.

    Study characteristics

    Study (year)nAge, median (range), yMale, %DiseaseConditioning, RI/MA, %Graft source, BM/PB, %GVHD prophylaxisF/U, median (range), mo
    Ahmed et al (2019)20,*,
     Haplo13933 (19-69)58HL100/070/30PT-Cy based52 (2-101)
     MSD45733 (18-66)56HL100/04/96CNI + (MMF 31%, MTX 48%, other 21%)37 (5-109)
    Bashey et al (2016)2145 (13-120)
     Haplo11651 (20-74)54Any60/4055/45PT-Cy + Tac/MMF
     MSD18153 (19-74)58Any46/541/99Tac/MTX
    Burroughs et al (2008)11,*
     Haplo2832 (14-62)46HL100/0100/0PT-Cy + Tac/MMF22 (4-62)
     MSD3833 (17-64)53HL100/00/100MMF/CNI24 (11-87)
    Devillier et al (2018)1726 (4-77)
     Haplo33≥60NRAML100/00/100PT-Cy based
     MSD31≥60NRAML84/166/94NR
    Dietrich et al (2016)19,*,NR
     Haplo59≥18NRNHL78/22NRPT-Cy + (MMF/CNI 86%, CNI 5%, NR 9%)
     MSD2024≥18NRNHLNRNRNR
    Dreger et al (2019)16,*,
     Haplo13258 (20-75)65DLBCL100/075/25PT-Cy ± CNI/MMF49 (12-73)
     MSD52555 (19-73)62DLBCL100/02/98CNI + (MMF 36%, MTX 45%, other 19%)48 (2-97)
    Gauthier et al (2018)18,*,
     Haplo6129 (17-68)54HL100/051/49PT-Cy + CNI/MMF24 (3-58)
     MSD9032 (12-67)63HL100/014/86CNI + (none 39%, MMF 35%, MTX 25%)24 (3-70)
    Ghosh et al (2016)14,*,
     Haplo18055 (18-75)64HL, NHL100/093/7PT-Cy ± CNI/MMF37 (6-73)
     MSD80754 (18-77)61HL, NHL100/02/98CNI + (MMF 31%, MTX 55%, other 14%)36 (3-76)
    Martinez (2017)12*,
     Haplo9831 (18-68)57HL90/1061/39PT-Cy + CNI + (MMF 94%, other 6%)27 (1-64)
     MSD33832 (18-67)43HL69/3110/89CNI + (MMF 27%, MTX 39%, other 34%)27 (1-76)
    Robinson et al (2018)15,*,,NR
     Haplo21841 (18-55)59AML, ALL40/6057/43PT-Cy + CNI/MMF
     MSD84342 (18-55)52AML, ALL16/8412/88CNI + (MMF 20%, MTX 64%, none 16%)
    Robinson et al (2018)15,*,,§NR
     Haplo21863 (55-76)59AML, ALL72/2870/30PT-Cy + CNI/MMF
     MSD86463 (55-76)58AML, ALL73/276/94CNI + (MMF 38%, MTX 45%, none 18%)
    Solh et al (2016)1346 (12-123)
     Haplo12850 (19-74)54Any59/4152/48PT-Cy + Tac/MMF
     MSD19853 (18-77)59Any47/532/98Tac/MTX 66%, Tac/MMF 25%, other 9%
    • The study by Bashey et al21 used the National Institutes of Health consensus criteria for cGVHD grading (mild vs moderate vs severe), whereas all other studies used the original classification system (limited vs extensive).

    • ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CNI, calcineurin inhibitor; DLBCL, diffuse large B-cell lymphoma; F/U, follow-up; Haplo, haploidentical; HL, Hodgkin lymphoma; MA, myeloablative; MMF, mycophenolate mofetil; MTX, methotrexate; NHL, non-Hodgkin lymphoma; NR, not reported; PB, peripheral blood; PT-Cy, posttransplant cyclophosphamide; RI, reduced intensity; Tac, tacrolimus.

    • * Multicenter study.

    • Registry study.

    • Recipient age 18 to 54 years.

    • § Recipient age ≥55 years.